IP-LAD
IP-LAD, or IPLAD, also known as IPR-LAD or as 6-isopropyl-6-nor-LSD, is an analogue of lysergic acid diethylamide developed by the team of David E. Nichols. In studies on mice, it was found to be approximately 40% the potency of LSD, compared to the 60% increase in potency seen with ETH-LAD, 2-fold potency increase of AL-LAD, and roughly equivalent potency of PRO-LAD. It is not a controlled substance in Canada as of 2025.